Radiopharmaceuticals have emerged as a high-growth track fiercely pursued by global pharmaceutical giants. From diagnostics to therapeutics, and from radionuclide conjugation to precision targeting, this field is embracing unprecedented development opportunities. The full agenda for the "Booming Radiopharmaceuticals Session" is officially released today. This session will gather top scientists, clinical experts, and industry leaders to focus on core issues including isotope supply, drug design, clinical translation, and industrialization. Join us in Shanghai this July to explore the unlimited potential of the future of nuclear medicine.

Special Session Agenda
Co-organizer: Baiyunshan Xihe Health

Opening Remarks
Yumin Zhang: Founder, Ankerui Biotech; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)
Hong Liu: Director of Scientific Research Management Department, GPHL; Chairman & General Manager, Baiyunshan Rare Nuclide Health

Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry and International Association of Advanced Materials; Vice Chairman, Radiopharmaceuticals Branch, Chinese Nuclear Society

Animal Model Selection for Preclinical-to-Clinical Translation of Radiopharmaceuticals
Conglin Zuo: Founder & Chairman, Hexin Pharmaceutical; Former Vice Chairman, JOINN Laboratories; Member, Drug Toxicology Committee, Chinese Pharmacological Society; Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association

Clinical Development Strategies for Radiotherapeutic Drugs in Oncology
Yan Gong: General Manager, Honghong Pharma；Special Advisor for Healthcare Practice, Bain & Company

Synergistic Innovation of RDC and ADC: The Next-Generation Paradigm for Precision Radiopharmaceutical Therapy
Zhican Qu: Chairman, Na'an Biotech

Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu (Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li: Partner, Stars Capital
Chunguang Liu: Managing Partner, Tailong VC
Feng Yu: Founder & CEO, ELI Radiopharma
Gang Chen: Founder & CEO, Jukang Litai
Xun Zhu: Honorary Director-General, Tonacea New Drug Talent Club

Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals
Xiangsheng Ye: Chief Scientific Officer, AlphaGen Therapeutics

Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals？
Xiang Li (Moderator): Global Partner of Fosun; Senior Vice President, Fosun Pharma; Co-President & Chief Scientific Officer, Innovative Drug Division; CEO, Fosun New Drugs
Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub
Peng Yu: Medical Lead, Radiopharmaceutical R&D, AstraZeneca